Isotiorga (Isotretinoin)

Isotretinoin binds to retinoic acid receptors in the nucleus, altering gene expression that controls skin cell growth and sebaceous gland activity. This results in smaller, less active glands, lower sebum production, and reduced inflammation, which together diminish severe acne lesions.

The dose of Isotiorga is individualized by the prescribing clinician based on the patient’s weight, severity of acne, and laboratory results. The prescriber determines the appropriate strength, frequency, and duration of therapy.

Isotiorga is classified as pregnancy category X because isotretinoin is highly teratogenic. It must not be used during pregnancy, and effective contraception is required before, during, and after treatment. Use while breastfeeding is also not recommended.

To order Isotiorga, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isotiorga (isotretinoin) is a systemic retinoid and is generally more effective for severe, treatment‑resistant acne than oral antibiotics or topical agents. Compared with other retinoids such as acitretin, isotretinoin has a shorter half‑life and is specifically approved for severe acne, though both share similar safety considerations.

Isotiorga should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Isotiorga is taken orally, usually as a capsule swallowed with a full glass of water. It may be prescribed to be taken with food to improve tolerability, but patients should follow the specific instructions provided by their healthcare professional.

The most serious risks include severe depression or suicidal ideation, significant liver enzyme elevation indicating hepatotoxicity, teratogenic birth defects if exposure occurs during pregnancy, and pseudotumor cerebri, a rare form of increased intracranial pressure.

Isotiorga should not be used by pregnant women, women planning pregnancy without reliable contraception, individuals with known hypersensitivity to isotretinoin or other retinoids, patients with uncontrolled liver disease or severe hyperlipidaemia, and anyone for whom the prescriber determines the risks outweigh the benefits.